Differentiated thyroid cancer (DTC) is the most common endocrine malignancy with a
growing incidence worldwide. The initial conventional management is surgery, followed by …

Appropriate dosing of adjuvant radioactive iodine for differ... : Current Opinion in Oncology
Appropriate dosing of adjuvant radioactive iodine for differentiated thyroid cancer : Current …

Radioiodine (131 I) therapy (RAI) has been utilized for treating differentiated thyroid cancer
(DTC) for decades, and its uses can be characterized as remnant ablation, adjuvant therapy …

I-131 therapy of differentiated thyroid cancer (DTC) was first performed in 1943 [1]. Since
then, seven decades have passed, and the worth and efficacy of I-131 therapy in DTC …

Summary background Justification for adjuvant radio‐iodine (I‐131) therapy in differentiated
thyroid cancer (DTC) is purely based on retrospective data. This is true for ablative therapy …

Aim For many years, thyroid surgery and radioiodine therapy for thyroid remnant ablation (ie
post-operative RaIT) have been the first-line therapeutic approaches in differentiated thyroid …

The treatment of differentiated thyroid cancer continues to move away from a 'one size fits
all'approach to a process of tailored therapeutic decision-making that incorporates disease …

Differentiated thyroid cancer is the most frequent type of thyroid cancer with an increasing
incidence in the last decades. The initial management is represented by surgical treatment …

Differentiated thyroid cancer (DTC) is the most common endocrine malignancy and the fifth
most common cancer in women. DTC therapy requires a multimodal approach, including …

Differentiated thyroid cancers are typically iodine-avid and can be effectively treated with
radioiodine. In most patients, radioiodine treatment is done for ablation of residual tissue …